Skip to content

2025/03

Treatment of MDR Gram-negative bacilli

f3b5d87da5acf2c8d79ff55edb954115_MD5.jpeg

Green, susceptibility anticipated to be >80%; yellow, susceptibility anticipated to be 30% to 80%; red, intrinsic resistance or susceptibility anticipated to be <30%. 1, US Food and Drug Administration–approved agent; 2, synthetic tetracycline derivative; 3, imipenem-cilastatin–relebactam; 4, synthetic aminoglycoside; 5, polymyxin class. Abbreviations: KPC, Klebsiella pneumoniae carbapenemase; NDM, New Delhi metallo-β-lactamase. (Tamma et al., 2024)